WARNING: “Buffett Indicator” flashing for first time in 50 years

Warren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.

Take these 4 steps today to protect your retirement NOW

John J. Trizzino net worth and biography

John Trizzino Biography and Net Worth

CFO of Novavax

Mr. Trizzino is executive vice president, chief business officer, chief commercial officer and interim chief financial officer with responsibility for global commercial strategy and execution and oversight of IT, investor and public relations, and corporate affairs. He has broad experience in publicly held companies and in vaccines, with previous roles overseeing commercialization, policy, strategy, business development, financing, and investor and public relations. Since rejoining Novavax in 2014, he has held roles of increasing responsibility, including chief financial officer and senior vice president of commercial operations. Mr. Trizzino served as CEO of Immunovaccine in 2011, successfully leading the company into clinical development while securing the funding commitments required to advance the company’s lead candidate. Earlier in his career, Mr. Trizzino held leadership roles at several companies with a focus in infectious disease vaccine markets, including MedImmune, LLC (now AstraZeneca), ID Biomedical and Henry Schein, Inc. Mr. Trizzino holds a bachelor of science degree from Long Island University, CW Post and a master of business administration degree from New York University, Stern School of Business.

What is John J. Trizzino's net worth?: The estimated net worth of John J. Trizzino is at least $71,487.90 as of September 14th, 2021. Mr. Trizzino owns 8,217 shares of Novavax stock worth more than $71,488 as of December 21st. This net worth evaluation does not reflect any other assets that Mr. Trizzino may own. Additionally, Mr. Trizzino receives a salary of $670,550.00 as CFO at Novavax. Learn More about John J. Trizzino's net worth.
How old is John J. Trizzino?: Mr. Trizzino is currently 64 years old. There are 6 older executives and no younger executives at Novavax. The oldest executive at Novavax is Mr. Richard P. Crowley, Executive VP & COO, who is 67 years old. Learn More on John J. Trizzino's age.
What is John J. Trizzino's salary?: As the CFO of Novavax, Inc., Mr. Trizzino earns $670,550.00 per year. There are 2 executives that earn more than Mr. Trizzino. The highest earning executive at Novavax is Mr. John Charles Jacobs M.B.A., President, CEO & Director, who commands a salary of $1,330,000.00 per year. Learn More on John J. Trizzino's salary.
How do I contact John J. Trizzino?: The corporate mailing address for Mr. Trizzino and other Novavax executives is 21 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. Novavax can also be reached via phone at (240) 268-2000 and via email at [email protected]. Learn More on John J. Trizzino's contact information.
Has John J. Trizzino been buying or selling shares of Novavax?: John J. Trizzino has not been actively trading shares of Novavax during the last ninety days. Most recently, John Trizzino sold 7,501 shares of the business's stock in a transaction on Tuesday, September 28th. The shares were sold at an average price of $209.92, for a transaction totalling $1,574,609.92. Learn More on John J. Trizzino's trading history.
Who are Novavax's active insiders?: Novavax's insider roster includes Stanley Erck (CEO), Gary Evans (Director), Gregory Glenn (Insider), John Herrmann, II (President, CEO & Director), Rachel King (Director), Michael McManus, Jr. (Director), David Mott (Director), John Trizzino (CFO), and James Young (Director). Learn More on Novavax's active insiders.
Are insiders buying or selling shares of Novavax?: During the last twelve months, insiders at the biopharmaceutical company sold shares 3 times. They sold a total of 62,312 shares worth more than $866,211.80. The most recent insider tranaction occured on June, 21st when Director James F Young sold 7,500 shares worth more than $105,675.00. Insiders at Novavax own 1.0% of the company. Learn More about insider trades at Novavax.
Information on this page was last updated on 6/21/2024.

John J. Trizzino Insider Trading History at Novavax

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
9/28/2021	Sell	7,501	$209.92	$1,574,609.92
9/20/2021	Sell	7,500	$227.57	$1,706,775.00
9/14/2021	Sell	7,499	$236.61	$1,774,338.39	8,217
5/7/2021	Sell	190	$176.63	$33,559.70	704
5/5/2021	Sell	3,022	$185.46	$560,460.12	704
4/7/2021	Sell	191	$178.03	$34,003.73	704
4/5/2021	Sell	3,021	$190.10	$574,292.10	704
3/9/2021	Sell	190	$168.09	$31,937.10	704
3/5/2021	Sell	3,021	$163.46	$493,812.66	704
2/9/2021	Sell	194	$324.50	$62,953.00	704
2/5/2021	Sell	3,022	$290.46	$877,770.12	704
1/7/2021	Sell	506	$124.17	$62,830.02	5,481
1/5/2021	Sell	17,407	$112.00	$1,949,584.00	5,481
9/29/2020	Sell	18,321	$107.29	$1,965,660.09	48,408
8/18/2020	Sell	42,788	$148.78	$6,365,998.64	16,336
9/11/2019	Sell	5,578	$5.72	$31,906.16	4,800
5/14/2018	Buy	50,000	$1.64	$82,000.00	138,965
9/22/2016	Buy	46,000	$2.17	$99,820.00	85,564
1/31/2015	Buy	6,611	$3.63	$23,997.93
6/17/2014	Buy	5,500	$4.51	$24,805.00
6/16/2014	Buy	16,500	$4.51	$74,415.00

John J. Trizzino Buying and Selling Activity at Novavax

Novavax Company Overview

Novavax, Inc., a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. It focuses on urgent health challenges, which is evaluating vaccines for COVID-19, influenza, and COVID-19 influenza combination. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It is also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.

Today's Range

Now: $8.70

$8.37

$8.89

50 Day Range

MA: $9.13

$7.22

$12.62

2 Week Range

Now: $8.70

$3.53

$23.86

Volume

6,086,848 shs

Average Volume

9,218,745 shs

Market Capitalization

$1.39 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.02

AI breakthrough about to upend industry

From Porter & Company | Ad

Everyone is talking about AI right now. The talk has been endless ever since ChatGPT was released to the market in late 2022. You might think it’s way too late to invest in AI. But here’s the thing.

I urge you to watch it now.

John Trizzino Biography and Net Worth

What is John J. Trizzino's net worth?

How old is John J. Trizzino?

What is John J. Trizzino's salary?

How do I contact John J. Trizzino?

Has John J. Trizzino been buying or selling shares of Novavax?

Who are Novavax's active insiders?

Are insiders buying or selling shares of Novavax?